Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Move Over Turing, Valeant – Mylan Next Target For Price Scrutiny

Executive Summary

So far, most of the attention on drug price increases has focused on Turing Pharmaceuticals AG and Valeant Pharmaceuticals International Inc. But Mylan NV soon could be in the bull's-eye of payers and lawmakers after hiking the prices of 24 of the firm's products by more than 20% in the past six month, with seven of those medicines' costs spiking more than 100%, Wells Fargo analyst David Maris said in a new report.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts